Loading
Twelve cycles of temozolomide after radiotherapy lengthened survival in grade 3 glioma without 1p/19q codeletion, while giving temozolomide during radiotherapy added nothing in these tumours.
Phase 3 factorial trial of 745 adults with newly diagnosed anaplastic glioma without 1p/19q codeletion randomised to radiotherapy alone, with concurrent temozolomide, with 12 cycles of adjuvant temozolomide, or with both.
Adjuvant temozolomide improved overall survival (hazard ratio 0.65; five-year survival 55.9 versus 44.1 percent); concurrent temozolomide did not, and later analysis showed benefit was confined to IDH-mutant tumours.
Radiotherapy followed by a year of temozolomide is the standard for grade 3 IDH-mutant astrocytoma; concurrent temozolomide is not needed, and IDH-wild-type tumours behave and are treated like glioblastoma.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Temozolomide.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Temozolomide.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Temozolomide.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Temozolomide.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Temozolomide.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Temozolomide.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Temozolomide.
Shares Astrocytoma, IDH-mutant (grades 2 to 4), Temozolomide.